Stong Biomarker for Parkinson’s Disease
High frequencies bands (Gamma) recorded in the motor cortex are strongly related to prokinetic activities.
GammaPark correlates to dyskinetic state in both patients and 6-OHDA rat model and can be used as a powerful biomarker to assess antikinetic and/or prokinetic effects of a compound in development.
- Expressed in PD patients treated by L-DOPA (levodopa)
- Objective, non tremor related
- Exclusively revealed by Cue® and EEG
Chronic L-DOPA treated patients show a specific increase in the Gamma frequencies while dyskinesia start to appear again (often reffered to as the end of the Honey moon).
- Metabolized into Dopamine, Levodopa (L-DOPA) is to date the gold strandard for treating PD patients.
- Chronic L-DOPA exposure generates several side-effects such as motor complications (L-DOPA Induced Dyskinesia or LID).
- L-DOPA treatment stops BetaPark™ transiently but enhances GammaPark™ at the same time.
GammaPark™ is Pharmacosensitive
- GammaPark™ is enhanced by administration of dopamine agonists.
- Chronic expression of GammaPark™ mirrors patient LID condition.
- Targeting GammaPark™ is a solid strategy to objectively assess your compound efficacy on LID.
- GammaPark™ modulation can be used to compare different drugs effects over time.
Time course of GammaPark™ activity when modulated by different dopamine agonists.
- This Time-frequency map shows how GammaPark™ is enhanced by an acute administration of a dopamine agonist in the 6-OHDA Rat.
- GammaPark™ remains stable over a time period of 4 hour post injection.
- The intensity of GammaPark™ directly correlates with an increase of LID.
The right dose of Amantadine lowers GammaPark™ while stopping BetaPark at the same time.
for your Parkinson’s Programs
Markers: beta and gamma oscillations, Multisite coherence
Programs: Lead selection (screening of small libraries of compounds), lead validation (dose-response effect, pharmacokinetic), disease modifying therapeutic potential, rodent model phenotyping